Protagonist Therapeutics company information, Employees & Contact Information

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 Oak Ridger

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 The Ames Tribune

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 Cincinnati Enquirer

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials ts2.tech

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 ACCESS Newswire

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs ts2.tech

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference PR Newswire

Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications ACCESS Newswire

Oklahoma City News - The Oklahoman FinancialContent

Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire

Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program PR Newswire

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis PR Newswire

Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire

Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists PR Newswire

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113) PR Newswire

Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association PR Newswire

Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program PR Newswire

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 PR Newswire

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda Yahoo Finance

Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma PR Newswire

Leading Biotech Protagonist Therapeutics Lines Up Three Major Investment Conferences This September Stock Titan

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232 PR Newswire

Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen PR Newswire

Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications PR Newswire

Protagonist Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire

Protagonist Therapeutics Reports First Quarter 2018 Financial Results PR Newswire

Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera PR Newswire

Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors PR Newswire

Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia PR Newswire

Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology PR Newswire

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 Stock Titan

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity Fall River Herald News

Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis PR Newswire

Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200 PR Newswire

Protagonist Therapeutics Announces Pricing of Initial Public Offering PR Newswire

Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 PR Newswire

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update Detroit Free Press

Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment PR Newswire

Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease PR Newswire

Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs into Clinical Development PR Newswire

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill Newswire.com

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate ACCESS Newswire

Protagonist Therapeutics Names William A. Hodder as Senior Vice President, Corporate Development PR Newswire

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress ACCESS Newswire

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor ACCESS Newswire

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences azcentral.com and The Arizona Republic

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 Worcester Telegram

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update Democrat and Chronicle

Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress CNN

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 | Daily Courier FinancialContent

User FinancialContent

PTGX Stock Price and Chart — NASDAQ:PTGX TradingView

Protagonist Therapeutics Inc (PTGX) Stock Price, Trades & News GuruFocus

About Us FinancialContent